ExpressionEdits raises £10.2m in seed funding to advance AI-driven protein expression technology.
The seed round was co-led by Octopus Ventures and redalpine to support preclinical candidate selection and pipeline development.
ExpressionEdits develops a computational gene editing platform that uses artificial intelligence and proprietary intron technology to optimise protein expression. The biotechnology firm operates from its headquarters in Cambridge.
ExpressionEdits has secured £10.2m in a seed funding round co-led by Octopus Ventures and redalpine. Additional participation came from BlueYard Capital, Wilbe Capital, Acequia Capital, Amino Collective, and Hawktail. The capital will be directed towards advancing candidate selection for preclinical trials and building out a pipeline focused on therapeutic proteins that have historically presented manufacturing difficulties.
Originating from University of Cambridge research, the company deploys an AI-powered platform to integrate biological data with machine learning algorithms. This genetic syntax engine aims to automate gene design optimisation and unlock the production of challenging therapeutic proteins.
From the founder
"At ExpressionEdits, we’re revolutionizing gene expression by putting introns back where they belong, resulting in significant improvements in production"
Kärt Tomberg
CEO & Co-Founder at ExpressionEdits
Investor perspective
"We believe that the ExpressionEdits platform can become the fabric for any protein expression system, from antibody manufacturing to in vivo therapeutics."
Hugo Villanueva
Investor, Octopus Ventures
Use of funds
- 01Fund research and development
Investors
Hugo Villanueva
Octopus Ventures
Michael Sidler
redalpine
BlueYard Capital
Wilbe Capital
Acequia Capital
Amino Collective
Hawktail
Categories
About the company
ExpressionEdits
ExpressionEdits uses artificial intelligence and proprietary intron technology to optimise protein expression.